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Abstract 
Purpose: This study aimed to determine if 1) consumption of caffeine improves endurance 
cycling performance in women, and 2) sex differences exist in the magnitude of the ergogenic 
and plasma responses to caffeine supplementation.  
Methods: Twenty-seven (11 women and 16 men) endurance-trained cyclists and triathletes 
participated in this randomized, double-blind, placebo-controlled, crossover study. Participants 
completed an incremental exercise test to exhaustion, two familiarization trials and two 
performance trials. Ninety minutes prior to the performance trials participants ingested opaque 
capsules containing either 3 mg·kg
-1
 body mass of anhydrous caffeine or a placebo. They then 
completed a set amount of work (75% of peak sustainable power output) in the fastest possible 
time. Plasma was sampled at baseline, pre- and post-exercise for caffeine. Strict standardization 
and verification of diet, hydration, training volume and intensity, and for women, contraceptive 
hormone phase was implemented.  
Results: Performance time was significantly improved following caffeine administration in 
women (placebo: 3863±419s, caffeine: 3757±312s; p=0.03) and men (placebo: 3903±341s, 
caffeine: 3734±287s; p<0.001). The magnitude of performance improvement was similar for 
women [4.3% (0.4-8.2%); mean (95% CI)] and men [4.6% (2.3-6.8%)]. Plasma caffeine 
concentrations were similar between sexes before exercise, but significantly greater in women 
after exercise (p<0.001).  
Conclusions: Ingestion of 3 mg·kg
-1
 body mass of caffeine enhanced endurance exercise 
performance in women. The magnitude of the performance enhancement observed in women 
was similar to that of men, despite significantly greater plasma caffeine concentrations following 
exercise in women. These results suggest the current recommendations for caffeine intake (i.e. 3-
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6 mg·kg
-1
 caffeine prior to exercise to enhance endurance performance), which are derived 
almost exclusively from studies on men, may also be applicable to women. Key words: Exercise 
Performance; Ergogenic aids; Central Nervous System Stimulants; Physiological Effects of 
Drugs; Sex differences 
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Introduction 
The ergogenic potential of caffeine on endurance performance tasks lasting approximately 1h has 
been well documented and summarised in a number of reviews (1, 2). Studies investigating the 
effects of caffeine on endurance exercise performance have examined the influence of several 
factors on the ergogenic response including the dose (3), timing (4), environmental conditions 
(5) and method of ingestion (6). However, these studies exclusively used male participants. 
Indeed, <10% of the 435 participants from 21 studies included in a systematic review of the 
effect of caffeine on endurance time trial performance were women (1); whilst in a more recent 
systematic review of the effect of caffeine-containing energy drinks on physical performance in a 
variety of sport disciplines, female participants comprised <20% of the total sample of 634 
participants (7).  Evidently, research inclusive of female participants is warranted.  
 
Results of studies investigating the effect of caffeine on exercise performance in women are 
mixed, with some studies reporting a significant ergogenic effect of caffeine (3-6 mg·kg
-1
 body 
mass; BM) (5, 8-11), whilst others report no effect when the same dose of caffeine was ingested 
(12-14). Variation in the ergogenic potential of caffeine among studies involving women may be 
explained, at least in part, by sex hormone status. Previous studies have demonstrated that 
endogenous and exogenous (e.g. oral contraceptives) female sex hormones have the potential to 
influence physiological responses to exercise (15-17) and exercise capacity (18, 19). Oral 
contraceptives, which are used with high prevalence (~50-70%) in young women from Western 
countries (20, 21), have also been found to affect the metabolism of caffeine following ingestion 
(22). Whether the reduced caffeine clearance rate in women taking oral contraceptives, and 
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subsequent increased accumulation of caffeine within the body, influences the ergogenic 
potential of caffeine has yet to be elucidated. 
 
To date, no studies have directly compared the ergogenic effects of caffeine in women and men 
using the same exercise protocol. Lane et al. (10) reported similar improvements in cycling time 
trial performance after caffeinated chewing gum was ingested in groups of men and women. 
However, the cycling time trial protocol was different between sexes (men were required to 
cycle ~44 km and women ~29 km). Whilst this data provides some evidence that the ergogenic 
response may be similar in women and men, the different protocols make direct comparisons 
between groups problematic. In contrast, two separate studies, one with men (23) and the other 
with women (24), using the same exercise protocols reported different findings in relation to the 
dose-response effect of caffeine on rowing performance. Bruce et al. (23) investigated the effects 
of ingesting 6 and 9 mg·kg
-1
 BM doses of caffeine or a placebo on the performance of 8 well-
trained male rowers in a 2000 m time trial (~7 min duration). These researchers reported a 1.2% 
improvement in performance with both doses. However, only a high dose (9 mg·kg
-1
 BM) was 
found to positively influence performance in women (24). Therefore, it is unclear whether 
caffeine exerts similar ergogenic effects in women and men.  
 
This study aims to determine whether 1) consumption of caffeine improves endurance cycling 
performance in women, and 2) sex differences exist in the magnitude of the ergogenic and 
plasma responses to caffeine. To enable accurate results and comparisons between sexes, this 
study was conducted in trained, familiarised athletes under stringently controlled testing 
conditions, including timing of testing, sex hormone status, and hydration and dietary 
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standardisation procedures. Due to the similarities in both the training status of participants and 
the mode of exercise (cycling) employed between the current study and the study conducted by 
Lane et al. (10) it was hypothesized that 1) consumption of caffeine would improve endurance 
cycling performance in women, 2) the ergogenic effect would be similar between sexes, and 3) 
women would have higher post-exercise plasma caffeine concentrations compared to men.   
 
Methods  
Participants  
Twenty-seven endurance-trained cyclists and triathletes (11 women and 16 men) were recruited 
to participate in this randomized, double-blind, placebo-controlled, crossover study. The 
inclusion criteria were as follows: (a) aged 18–45 years (b) raced competitively for at least one 
season; (c) consistently high training volume and intensity for at least the last two months; and 
(d) self-described satisfactory health status. Women were also required to be regularly taking an 
oral contraceptive pill for at least three months. Participants were excluded if they reported: (a) 
current injury or disease state that may affect participation, confirmed by completion of a 
modified Sports Medicine Australia Pre-Exercise Screening System (25); (b) currently taking 
diuretics or have been treated with diuretics within the previous 4 weeks; (c) allergies to heparin 
or latex; (d) donated blood within the previous 3 months; and (e) regular cigarette smoking, 
cessation within the last six months, or exposure to environmental tobacco smoke. All 
participants provided written informed consent; the study was approved by the Medical Research 
Ethics Committee of The University of Queensland and Human Research Ethics Committee of 
Griffith University, Queensland, Australia.   
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Pre-trial standardization  
A standardized pre-packaged diet was provided for the 24 h preceding each experimental trial for 
women (180 kJ·kg
-1
 BM, providing 7 g·kg
-1
 BM of carbohydrates) and men (200 kJ·kg
-1
 BM, 
providing 7.5 g·kg
-1
 BM of carbohydrates). A pre-exercise meal (40 kJ·kg
-1
 BM, providing 1.5 
g·kg
-1
 BM of carbohydrates for women; 42 kJ·kg
-1
 BM, providing 2 g·kg
-1
 BM of carbohydrates 
for men) was consumed 2 h before the commencement of each time trial.  
Dietary analysis software (FoodWorks
®
, Xyris Software, Australia) and the Nutrition 
Information Panels of each food item were used to ensure the foods selected for each participant 
met the carbohydrate and energy intake guidelines (26). Our previous experience has indicated 
that very high intakes of energy and carbohydrate are not as well tolerated by some women 
cyclists. Therefore, we aimed for slightly lower intake for women to keep the intake of 
carbohydrate and energy as consistent as possible within and between participants. To avoid any 
influence of circadian variance, experimental trials were performed at the same time of the day 
(mornings) and separated by ≥5 days to enable a wash-out period between each session.  
 
On each day of testing, participants confirmed and signed written compliance with the pre-trial 
study requirements, including: (a) following a hydration protocol to minimise variation in pre-
exercise hydration state; (b) following pre-trial dietary requirements involving completion of a 
food diary and avoiding consumption of substances that potentially affect the metabolism of 
caffeine for 24 h e.g. cruciferous vegetables, charcoal broiled beef, aspirin and cimetidine; (c) 
completing the habitual caffeine consumption questionnaire (27); (d) avoiding consumption of 
caffeine-containing substance/s, vigorous exercise and alcohol within 24 h of testing. 
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Contraceptive hormone phase 
Women were asked to map their oral contraceptive use to indicate when active and inactive pills 
were consumed throughout the cycle, according to previously published methods (28). In the 4 
weeks (i.e. 1 cycle) leading up to and during testing, women were asked to take the oral 
contraceptive at the same time each day, preferably before 20:00 each night, in order to minimise 
variability in exogenous hormone concentration at the time of testing. Testing for women taking 
monophasic and triphasic oral contraceptive formulations occurred in the high hormone phase 
(between days 15-28 and days 22-28 of the active pill phase, respectively), to optimise 
consistency of the hormone profile across the monophasic and triphasic pill types. Ovulation 
testing was performed to confirm cycle control by exogenous hormones. Participants were 
provided with a home urine ovulation detection kit (Discover ® 7-Day Pregnancy Planning kit, 
Church and Dwight Australia Pty Ltd.) and instructed to follow the directions on the packaging 
to perform the ovulation test for seven consecutive days during their cycle, prior to the testing 
sessions. Negative ovulation results over 7 consecutive days indicated efficacious exogenous 
control of ovarian hormones.   
 
Preliminary testing  
Participants attended the laboratory on three occasions prior to the experimental trials. The first 
visit involved medical screening, the completion of a habitual caffeine consumption 
questionnaire and an incremental exercise test to exhaustion on an electromagnetically-braked 
cycle ergometer (Lode Excalibur Sport, Lode, Groningen, The Netherlands), to determine 
participants’ individual peak aerobic capacity (  O2peak) and peak sustainable power output 
(PPO). The metabolic system’s (Medgraphic Ultima, MGC Diagnostics and Medisoft, USA) gas 
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analysers were calibrated as per the manufacturer’s instructions using a certified calibration 
standard gas mixture (BOC gases, Brisbane, Australia). The system pneumotach was also 
calibrated as per the manufacturer’s instructions using a 3 L calibration syringe (Hans Rudolph 
Inc., Shawnee, Kansas, USA). Participants began cycling at 100 W (women) and 150 W (men), 
with 15 W increments every 30 s until volitional fatigue. Expired air was sampled every 15 s and 
analysed according to the method described by Laursen et al. (29)     2peak was recorded as the 
highest    2 reading averaged over two consecutive readings. Calibration readings were verified 
after each test. Laboratory visits two and three were familiarisation trials involving the full 
exercise protocol. Our laboratory has previously shown time trials to be highly reliable 
(coefficient of variation = 0.9 ± 0.7%) for trained male cyclists following a familiarisation trial 
(30). Two familiarisation sessions were performed to establish a self-selected warm-up and 
ensure the accurate calculation of individual linear factors. The participants’ linear factors were 
determined based on individual PPO and was initially chosen to enable 75% PPO to be achieved 
at ~100 rpm. The target amount of work was calculated according to the formula: Total work (J) 
= 0.75·PPO·3600 
 
Experimental trials 
Each participant completed two time trials, in a random order, under double-blinded conditions. 
The order of trials was randomized by a person independent from the study using a random 
number generating process.  
 
Upon arrival at the laboratory, a urine sample was collected and osmolality measured to confirm 
euhydration using a vapour pressure osmometer (Wescor 5500XR, Logan, UT). If urine 
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osmolarity was ≥830 msom, participants were required to consume water and provide a second 
urine sample before continuing with testing. Height and body mass were measured using a 
stadiometer (Seca, Birmingham, UK) and electronic scales (A&D Mercury, Pty Ltd, Thebarton, 
AUS), respectively, for the calculation of body mass index (BMI; kg∙m-2). A venous blood 
sample (5 mL) was collected from the antecubital vein using a 21 G needle into a lithium 
heparin-prepared vacutainer by a qualified phlebotomist. Ninety minutes before exercise, 
participants ingested opaque capsules containing either anhydrous caffeine (3 mg·kg
-1
 BM; 
Sigma-Aldrich) or a placebo containing approximately 400 mg of Metamucil
® 
(100% psyllium 
husk fibre).  
 
Participants completed the same self-selected warm up determined during the familiarisation 
trials in both time trials. Immediately prior to the commencement of the time trial and 
immediately after the completion of the time trial, additional venous blood samples (5 mL) were 
collected. Time trials required participants to complete the set amount of work as fast as 
possible. Subjective ratings of perceived exertion (RPE) and heart rate (HR) (Polar Electro, 
Kempele, Finland) were recorded after each 10% of total work throughout the time trial. 
Participants were able to view their HR, cadence and power output for the first 10% of each time 
trial; the only information available to participants for the remainder of the trial was total work 
percentage. Participants ingested 3 mL·kg
-1
 BM of 6% carbohydrate-electrolyte beverage during 
the warm-up, as well as upon completion of 30% and 60% of the target amount of work. Upon 
completion of all trials, participants attempted to identify the order of treatment for the trials, rate 
their confidence with this order and judge which trial they perceived to be their best 
performance.  
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Blood analysis 
After each venipuncture, vacutainers were placed on ice for <2 h prior to centrifugation at 7000 x 
g at 5°C for 10 min. Plasma was removed, placed into separate storage tubes and stored at -80°C 
until later analysis. All samples were analysed for caffeine using an automated reversed-phase 
high-performance liquid chromatography system as outlined by Desbrow and colleagues (31). 
The intra-assay coefficient of variation for caffeine was 3.9% (analysis for 84 duplicate samples 
pooled containing 41 ± 18 mol∙L-1 caffeine).  
 
Statistical analysis 
A sample size calculation indicated that to detect a 2% difference in performance (assuming 65 
min to complete time trial = 80 s) with a SD of 85 s with alpha of 0.05 and 80% power, 11 
participants would be required (paired t-test) (Power and Sample Size Software, Vanderbilt 
University, TN).  
 
Analyses were performed using SPSS (version 22.0, SPSS, Inc., IL, USA). Normality of 
distribution for outcome measures was tested using the Shapiro-Wilk test. Where data were not 
normally distributed (i.e.   O2peak, PPO, usual caffeine intake and female performance time) data 
were log transformed and rechecked for normality. Treatment, sex, and treatment x sex 
differences in performance time, RPE and HR values were analysed using two-way repeated 
measures analysis of variance. Where significant main effects were observed, pair-wise 
Bonferroni corrected comparisons were conducted to identify the nature of the differences. 
Paired sample t-tests were completed to determine whether plasma caffeine concentrations 
differed pre- to post-exercise for both sexes. Unpaired t-tests were completed to determine 
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whether there were sex differences in plasma caffeine concentrations. Pearson’s correlation 
coefficient analyses were completed to determine whether relationships existed between 
performance time and plasma caffeine concentrations. Significance was set at an alpha level of 
<0.05. All data are reported as mean ± SD, or median (interquartile range) for nonparametric 
analyses, as appropriate.  
 
Results 
Participant characteristics are presented in Table 1. Analysis indicated that women had 
significantly lower BM (p < 0.001), BMI (p = 0.014),   O2peak (p = 0.001) and PPO (p < 0.001) 
compared to men. No significant differences in age (p = 0.318) or usual caffeine intake (p = 
0.168) was observed between sexes. All participants included in the analysis confirmed 
compliance with pre-trial study requirements, including abstinence from substances that 
influence caffeine metabolism. All testing procedures for women occurred in the high hormone 
phase (between days 15-28) of the oral contraceptive pill cycle and all women had negative 
ovulation results throughout testing, demonstrating efficacious control of ovarian hormone 
fluctuations.  Only one woman was taking a triphasic formulation, so no comparisons in the 
response to caffeine between women taking either monophasic or triphasic contraceptive 
pills were possible. All participants consumed the carbohydrate-electrolyte beverage during the 
warm-up and at 30% and 60% of the target amount of work in full. 
 
Performance time  
Performance results are displayed in Table 2. Results showed a significant main effect of 
treatment, with an average performance time improvement of 169 s [F(1, 25) = 21.91,  p < 
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0.001]  following caffeine compared to placebo. However, there was no significant main effect 
of sex [F(1, 25) = 1.02, p = 0.32], or sex x treatment interaction [F(1, 25) = 0.001, p = 0.98]. 
Percentage change in performance time was similar (p = 0.88) between men (4.6 ± 4.2%) and 
women (4.3 ± 5.8%) (Fig. 1).   
 
Rating of perceived exertion  
Results showed no main effect of treatment [F(1, 24) = 0.50, p = 0.49], indicating RPE did not 
significantly differ between the caffeine and placebo trials (Table 2). There was also no 
significant main effect of sex [F(1,24) = 1.17, p = 0.96] or a sex x treatment interaction [F(1,24) 
= 1.36, p = 0.26].  
 
Heart rate  
A significant main effect of treatment was observed, resulting in an average HR elevation of 6 
bpm [F(1/25), 29.21, p < 0.001] in the caffeine trials compared to placebo (Table 2). There was 
no significant main effect of sex [F(1/25), 0.003, p = 0.29], however, a significant sex x 
treatment interaction [F(1/25), 4.66, p = 0.04] was observed. For men, average HR was 
significantly higher in the caffeine (170 ± 13 bpm) trials compared to the placebo (163 ± 13 
bpm) trials (t(15) = -5.60, p < 0.001). There was also a significant difference in average HR 
between trials (t(10) = -2.33, p = 0.04) in women, with the average heart rate being 168 ± 8.5  
bpm  in the caffeine trials and 166 ± 12.6 bpm in the placebo trials. 
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Plasma caffeine concentrations  
Pre-exercise plasma caffeine concentrations were not significantly different (p = 0.41) between 
men (22.6 ± 4.7 μmol·L-1) and women (19.7 ± 8.5 μmol·L-1) (Fig. 2). Post-exercise plasma 
caffeine concentrations were significantly higher (p < 0.001) in women (32.3 ± 4.7 μmol·L-1) 
compared to men (23.0 ± 3.5 μmol·L-1). A significant increase in plasma caffeine concentration 
was observed in women from pre- to post-exercise (p = 0.008); no significant difference between 
pre- and post-exercise caffeine concentrations was observed in men.  
  
No significant relationship was observed between pre- or post-trial plasma caffeine concentration 
and percentage change in performance time with caffeine (compared to placebo) for women or 
men (all p > 0.05) (Fig. 3).  
 
Blinding success and adverse events  
There was no difference between sexes in the success of participant blinding; with 63.6% of 
women and 62.5% of men correctly identifying their trial. No participant reported adverse side 
effects during or after each testing session.  
 
Discussion 
This is the first study to directly compare the ergogenic response to caffeine using the same 
exercise protocol in women and men. Consistent with our hypothesis, the results suggest that 
caffeine enhances endurance cycling performance in women and the magnitude of this 
performance enhancement is similar to that observed in men. This occurred despite subtle 
differences in plasma caffeine concentrations and HR responses.  
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The present study showed that compared to placebo, cycling performance in women was 
improved by 4.3% when 3 mg·kg
-1
 BM of caffeine was ingested. This finding is consistent with 
the study by Lane et al. (10) who found significant improvements in endurance cycling 
performance in women after consumption of 3 mg·kg
-1
 BM of caffeine. In trained female soccer 
players, Lara et al. (32) demonstrated an improvement in the 1) average peak running speed 
during a sprint test, 2) total number of sprint bouts performed, 3) total running distance, and 4) 
total running distance covered at >18 km·h
-1
 with the ingestion of 3 mg·kg
-1 
BM of caffeine in 
the form of an energy drink, during a 2 x 40 min (including a 15-min half time) simulated game. 
In contrast, Anderson et al. (24) found mixed results in the rowing performance of competitive 
oarswomen, with significant improvements following 9 mg·kg
-1
 BM but not 6 mg·kg
-1
 BM of 
caffeine. Del Coso et al. (33) demonstrated that 3 mg·kg
-1 
BM of caffeine ingested in the form of 
an energy drink improved the running pace and increased the distance covered at a running speed 
of >18 km·h
-1
 in competitive female rugby players during a match competition. However, the 
maximal running speed during a repeated sprint test performed after competition was unaffected. 
Collectively, these studies highlight the variability in the ergogenic response to caffeine in 
women. The inconsistent outcomes reported among these studies may be due to the variable 
duration of exercise, or more likely, the potential influence of female sex hormones on 
performance measures. The present study was the first of its kind to use tight control and 
verification of sex hormone concentrations across testing sessions in female participants. 
Therefore, whilst other studies using female participants have reported mixed results, the 
ergogenic effects of caffeine observed in the current study with trained and familiarized athletes 
using an ecologically valid protocol under well-controlled experimental conditions, including sex 
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hormone status, carbohydrate availability and hydration status, suggest that caffeine is able to 
enhance endurance performance in women.  
 
The present study demonstrated a significant improvement in endurance cycling performance for 
women (4.6%) and men (4.3%) with 3 mg·kg
-1
 BM of anhydrous caffeine, compared to placebo. 
This finding is similar to that of Lane et al. (10) who found between 3-4% improvement in 
cycling time trial performance in both women and men following 3 mg·kg
-1
 BM of caffeinated 
chewing gum compared to placebo. Lane et al. (10) found no sex difference in ergogenic 
response, however in this study men were required to cycle a greater time trial distance than the 
women. The results of the present study provide evidence that the ergogenic response of men and 
women to caffeine is similar when both sexes complete an identical exercise task. Therefore, 
despite the current recommendations for caffeine use to enhance performance being based almost 
exclusively on studies involving men (34), the results of the present investigation suggest that 
these recommendations may also be applicable to women. 
 
Caffeine ingestion has been shown to elicit physiological changes in perceptual responses (RPE) 
(11), and HR variables (4), which may contribute to subsequent performance improvements (15). 
Caffeine is a potent adenosine A1 and/or A2a receptor antagonist that can alter perceptual 
responses during exercise (11). The present study showed no significant change in RPE between 
placebo or caffeine trials in either sex, despite an improvement in performance time. This 
suggests the enhancement in endurance performance during the caffeine trials occurred with no 
concurrent increase in perceptual response. These results support the findings by Astorino et al. 
(2) who found no significant change in RPE responses between caffeine and placebo trials in 
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men or women when undertaking a cycle to exhaustion protocol, similar to the protocol used 
within the current study. In a meta-analysis, Doherty and Smith (11) showed that RPE was likely 
to be reduced with caffeine ingestion prior to constant load exercise, whereas no difference in 
RPE between caffeine and placebo trials were observed in exercise to exhaustion protocols. As 
such, the present results indicate that despite participants performing at a higher intensity in the 
caffeine trial, their perception of effort did not concurrently increase.  
 
Average HR increased following caffeine ingestion in the present study, in accordance with 
observations from previous studies (9, 11). The present study demonstrated that the consumption 
of caffeine elicited a significant increase in average HR values in both men and women. These 
results are in accordance with those found by Bridge & Jones (9) who demonstrated a mean HR 
increase of 1.9 ± 0.9 bpm in trained male participants during exercise after ingesting 3 mg·kg
-1 
BM caffeine. In addition, Lara et al. (32) reported that average HR tended to be higher (~6 bpm) 
in caffeine trials compared to placebo trials in trained female soccer players, however these 
differences did not reach statistical significance. As performance time was similar between males 
and females, and there were no observed sex differences in HR responses, it appears that sex 
does not influence the effect of caffeine on heart rate.  
 
The metabolism of caffeine is largely dependent on genetics (CYP1A2 isoform of cytochrome 
P450), with some evidence of downstream enzymatic differences between sexes (35). Supporting 
our hypothesis, significantly greater post-exercise plasma caffeine concentrations were found in 
women compared to men in the present study. Given that there was no significant difference in 
endurance exercise performance between women and men, these results suggest that the 
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differences in plasma caffeine concentrations did not influence the ergogenic potential of 
caffeine. This is consistent with Skinner et al. (4), who only demonstrated significantly faster 
endurance cycling time trial performance when caffeine was administered 1 h prior to exercise, 
rather than when peak caffeine concentration coincided with the onset of exercise. Therefore, 
optimizing concentrations of caffeine in the bloodstream may not be related to enhanced 
performance. Moreover, no significant correlation between the pre- or post-trial plasma caffeine 
concentrations and the improvement in performance was observed in either sex. Both these 
results provide further evidence to suggest the ergogenic potential of caffeine is unlikely to be 
influenced by the relative concentration of caffeine in the bloodstream in either sex.  
 
Limitations 
This study has several limitations worthy of comment. First, there was no measure of plasma 
volume, body composition (other than body mass before the time trials) or change in hydration 
status following the time trials; therefore, we were unable to determine whether differences in 
plasma volume, fat mass and/or lean mass among participants may have explained the observed 
differences in plasma caffeine concentrations between sexes following exercise. Second, whilst 
we matched participants for training volume, competitive history and age, and expected 
differences between sexes in body composition and exercise performance parameters, the women 
appear to be less trained than the men. Overall sex differences in   O2peak may have influenced 
the effect of caffeine on performance outcomes, and should be further elucidated. Whilst there 
were no significant differences in usual caffeine intake between sexes, the mean usual caffeine 
intake of men was more than double that of women. There is a common assumption that 
compared to no or low usual caffeine intake, high usual caffeine intake reduces the ergogenic 
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potential of caffeine, and thus these individuals require greater acute doses of caffeine to 
maintain the ergogenic effect. However, this assumption is not supported by the available 
evidence (36), with previous studies suggesting usual caffeine intake does not influence serum 
caffeine concentrations, nor does it appear to affect the ergogenic potential of caffeine (37-39). 
The study’s relatively small sample size, in particular the small number of female participants, 
may have limited the ability to detect statistically significant changes in RPE and HR. Finally, 
whilst many studies have demonstrated ergogenic effects associated with caffeine ingestion, the 
possibility of known placebo effects associated with caffeine ingestion (40) must also be 
considered. Although the treatments were administered in a double-blind manner, the majority of 
participants (n = 14) correctly identified the placebo trials at the conclusion of the study. Hence 
there is the potential that the participant’s awareness of an ‘active’ intervention may have 
influenced subsequent performance. Nevertheless, the performance improvement of 4.3% for 
women, and 4.6% for men, after caffeine ingestion is somewhat greater than the magnitude of 
previously documented placebo effects (40). 
 
In summary, this study has shown that caffeine ingestion can enhance endurance exercise 
performance in both women and men, and the magnitude of this performance enhancement is 
similar in both sexes. These results indicate that current recommendations for caffeine intake for 
endurance athletes, which are derived almost exclusively from studies on men only, may also be 
applicable to women. 
  
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Acknowledgements 
This study was supported by The University of Queensland New Staff Research Start-Up Fund, 
Grant #2011001239. We would like to thank Amy Gibson, Hillary Mathison and Emily Neville 
for their assistance with data collection.  
 
Conflict of Interest 
The authors have no declared conflicts of interest. The results of the study are presented clearly, 
honestly, and without fabrication, falsification, or inappropriate data manipulation. The results of 
the present study do not constitute endorsement by the American College of Sports Medicine. 
  
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
References 
1. Ganio MS, Klau JF, Casa DJ, Armstrong LE, Maresh CM. Effect of caffeine on sport-
specific endurance performance: A systematic review. J Strength Cond Res. 2009;23(1):315-24. 
doi: 10.1519/JSC.0b013e31818b979a. PubMed PMID: ISI:000271400500046. 
2. Doherty M, Smith PM. Effects of caffeine ingestion on rating of perceived exertion 
during and after exercise: a meta-analysis. Scand J Med Sci Sports. 2005;15(2):69-78. PubMed 
PMID: ISI:000227776100002. 
3. Desbrow B, Biddulph C, Devlin B, Grant GD, Anoopkumar-Dukie S, Leveritt MD. The 
effects of different doses of caffeine on endurance cycling time trial performance. Journal of 
Sports Sciences. 2012;30(2):115-20. doi: 10.1080/02640414.2011.632431. PubMed PMID: 
WOS:000302102200001. 
4. Skinner TL, Jenkins DG, Taaffe DR, Leveritt MD, Coombes JS. Coinciding exercise 
with peak serum caffeine does not improve cycling performance. Journal of Science and 
Medicine in Sport. 2013;16(1):54-9. doi: 10.1016/j.jsams.2012.04.004. PubMed PMID: 
WOS:000314669700012. 
5. Pitchford NW, Fell JW, Leveritt MD, Desbrow B, Shing CM. Effect of caffeine on 
cycling time-trial performance in the heat. Journal of science and medicine in sport / Sports 
Medicine Australia. 2014;17(4):445-9. Epub 2013/08/13. doi: 10.1016/j.jsams.2013.07.004. 
PubMed PMID: 23932933. 
6. Doering TM, Fell JW, Leveritt MD, Desbrow B, Shing CM. The effect of a caffeinated 
mouth-rinse on endurance cycling time-trial performance. International journal of sport nutrition 
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
and exercise metabolism. 2014;24(1):90-7. Epub 2013/08/28. doi: 10.1123/ijsnem.2013-0103. 
PubMed PMID: 23980239. 
7. Souza DB, Del Coso J, Casonatto J, Polito MD. Acute effects of caffeine-containing 
energy drinks on physical performance: a systematic review and meta-analysis. European Journal 
of Nutrition. 2017;56(1):13-27. doi: 10.1007/s00394-016-1331-9. 
8. Astorino TA, Roupoli LR, Valdivieso BR. Caffeine does not alter RPE or pain perception 
during intense exercise in active women. Appetite. 2012;59(2):585-90. doi: 
10.1016/j.appet.2012.07.008. PubMed PMID: WOS:000309310000057. 
9. Bridge CA, Jones MA. The effect of caffeine ingestion on 8 km run performance in a 
field setting. Journal of Sports Sciences. 2006;24(4):433-9. PubMed PMID: 
ISI:000236285000010. 
10. Lane SC, Hawley JA, Desbrow B, Jones AM, Blackwell JR, Ross ML, et al. Single and 
combined effects of beetroot juice and caffeine supplementation on cycling time trial 
performanc. Applied Physiology Nutrition and Metabolism-Physiologie Appliquee Nutrition Et 
Metabolisme. 2013. Epub October 11, 2013. 
11. Cole KJ, Costill DL, Starling RD, Goodpaster BH, Trappe SW, Fink WJ. Effect of 
caffeine ingestion on perception of effort and subsequent work production. Int J Sport Nutr. 
1996;6(1):14-23. PubMed PMID: ISI:A1996TW88300003. 
12. Wallman KE, Goh JW, Guelfi KJ. Effects of caffeine on exercise performance in 
sedentary females. J Sport Sci Med. 2010;9(2):183-9. PubMed PMID: ISI:000278590100004. 
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
13. Demura S, Yamada T, Terasawa N. Effect of coffee ingestion on physiological responses 
and ratings of perceived exertion during submaximal endurance exercise. Perceptual and motor 
skills. 2007;105(3_suppl):1109-16. 
14. Jensen MB, Norager CB, Fenger-Grøn M, Weimann A, Møller N, Madsen MR, et al. 
Caffeine supplementation had no effect on endurance capacity in elderly subjects who had 
abstained from caffeine-containing nutrition for 8 hours. Journal of Caffeine Research. 
2011;1(2):109-16. 
15. Tarnopolsky MA. Sex differences in exercise metabolism and the role of 17-beta 
estradiol. Medicine and science in sports and exercise. 2008;40(4):648-54. Epub 2008/03/05. 
doi: 10.1249/MSS.0b013e31816212ff. PubMed PMID: 18317381. 
16. Devries MC, Hamadeh MJ, Phillips SM, Tarnopolsky MA. Menstrual cycle phase and 
sex influence muscle glycogen utilization and glucose turnover during moderate-intensity 
endurance exercise. American Journal of Physiology-Regulatory, Integrative and Comparative 
Physiology. 2006;291(4):R1120-R8. doi: 10.1152/ajpregu.00700.2005. PubMed PMID: 
16690766. 
17. Timmons BW, Tarnopolsky MA, Bar-Or O. Sex-based effects on the distribution of NK 
cell subsets in response to exercise and carbohydrate intake in adolescents. Journal of Applied 
Physiology. 2006;100(5):1513-9. doi: 10.1152/japplphysiol.01125.2005. PubMed PMID: 
16410379. 
18. Casazza GA, Suh SH, Miller BF, Navazio FM, Brooks GA. Effects of oral contraceptives 
on peak exercise capacity. Journal of applied physiology (Bethesda, Md : 1985). 
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
2002;93(5):1698-702. Epub 2002/10/17. doi: 10.1152/japplphysiol.00622.2002. PubMed PMID: 
12381756. 
19. Notelovitz M, Zauner C, McKenzie L, Suggs Y, Fields C, Kitchens C. The effect of low-
dose oral contraceptives on cardiorespiratory function, coagulation, and lipids in exercising 
young women: A preliminary report. American Journal of Obstetrics and Gynecology. 
1987;156(3):591-8. doi: https://doi.org/10.1016/0002-9378(87)90059-7. 
20. Greig AJ, Palmer MA, Chepulis LM. Hormonal contraceptive practices in young 
Australian women (</= 25 years) and their possible impact on menstrual frequency and iron 
requirements. Sexual & reproductive healthcare : official journal of the Swedish Association of 
Midwives. 2010;1(3):99-103. Epub 2010/12/03. doi: 10.1016/j.srhc.2010.06.001. PubMed 
PMID: 21122605. 
21. Fletcher PC, Bryden PJ, Bonin E. Preliminary examination of oral contraceptive use 
among university-aged females. Contraception. 2001;63(4):229-33. Epub 2001/05/30. PubMed 
PMID: 11376651. 
22. Patwardhan RV, Desmond PV, Johnson RF, Schenker S. Impaired elimination of caffeine 
by oral contraceptive steroids. The Journal of laboratory and clinical medicine. 1980;95(4):603-
8. Epub 1980/04/01. PubMed PMID: 7359014. 
23. Bruce CR, Anderson ME, Fraser SF, Stepto NK, Klein R, Hopkins WG, et al. 
Enhancement of 2000-m rowing performance after caffeine ingestion. Medicine and science in 
sports and exercise. 2000;32(11):1958-63. PubMed PMID: ISI:000165220600021. 
24. Anderson ME, Bruce CR, Fraser SF, Stepto NK, Klein R, Hopkins WG, et al. Improved 
2000-meter rowing performance in competitive oarswomen after caffeine ingestion. International 
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
journal of sport nutrition and exercise metabolism. 2000;10(4):464-75. PubMed PMID: 
ISI:000167098200010. 
25. Sports Medicine Australia. Sports Medicine Australia (SMA) pre-exercise screening 
system 2005 [cited 2014 1 August]. Available from: http://sma.org.au/wp-
content/uploads/2009/05/new_pre_screening.pdf. 
26. Jeacocke NA, Burke LM. Methods to standardize dietary intake before performance 
testing. International journal of sport nutrition and exercise metabolism. 2010;20(2):87-103. 
Epub 2010/05/19. PubMed PMID: 20479482. 
27. Skinner TL, Folling J, Leveritt MD, Coombes JS, Taaffe DR, Jenkins DG. Effect of a 
high carbohydrate meal on serum caffeine concentrations following caffeine ingestion. Journal of 
science and medicine in sport / Sports Medicine Australia. 2010;13(6):S25. PubMed Central 
PMCID: PMC2010. 
28. Schaumberg MA, Jenkins DG, Janse de Jonge XAK, Emmerton LM, Skinner TL. Three-
step method for menstrual and oral contraceptive cycle verification. Journal of Science and 
Medicine in Sport. 2017;20(11):965-9. doi: https://doi.org/10.1016/j.jsams.2016.08.013. 
29. Laursen PB, Shing CM, Jenkins DG. Temporal aspects of the VO2 response at the power 
output associated with VO2 peak in well trained cyclists - Implications for interval training 
prescription. Res Q Exerc Sport. 2004;75(4):421-6. PubMed PMID: ISI:000225825500009. 
30. Laursen PB, Shing CM, Jenkins DG. Reproducibility of a laboratory-based 40-km cycle 
time-trial on a stationary wind-trainer in highly trained cyclists. Int J Sports Med. 
2003;24(7):481-5. PubMed PMID: ISI:000185696700002. 
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
31. Desbrow B, Barrett CM, Minahan CL, Grant GD, Leveritt MD. Caffeine, cycling 
performance, and exogenous CHO oxidation: a dose-response study. Medicine and science in 
sports and exercise. 2009;41(9):1744-51. doi: 10.1249/MSS.0b013e3181a16cf7. PubMed PMID: 
ISI:000269338200009. 
32. Lara B, Gonzalez-Millán C, Salinero JJ, Abian-Vicen J, Areces F, Barbero-Alvarez JC, et 
al. Caffeine-containing energy drink improves physical performance in female soccer players. 
Amino Acids. 2014;46(5):1385-92. doi: 10.1007/s00726-014-1709-z. 
33. Del Coso J, Portillo J, Muñoz G, Abián-Vicén J, Gonzalez-Millán C, Muñoz-Guerra J. 
Caffeine-containing energy drink improves sprint performance during an international rugby 
sevens competition. Amino Acids. 2013;44(6):1511-9. 
34. Goldstein ER, Ziegenfuss T, Kalman D, Kreider R, Campbell B, Wilborn C, et al. 
International society of sports nutrition position stand: caffeine and performance. J Int Soc Sport 
Nutr. 2010;7:15. doi: 5 
10.1186/1550-2783-7-5. PubMed PMID: ISI:000274832500001. 
35. Nehlig A. Interindividual Differences in Caffeine Metabolism and Factors Driving 
Caffeine Consumption. Pharmacological reviews. 2018;70(2):384-411. Epub 2018/03/09. doi: 
10.1124/pr.117.014407. PubMed PMID: 29514871. 
36. Skinner TL, Jenkins DG, Leveritt MD, McGorm A, Bolam KA, Coombes JS, et al. 
Factors influencing serum caffeine concentrations following caffeine ingestion. Journal of 
science and medicine in sport. 2014;17(5):516-20. Epub 2013/08/13. doi: 
10.1016/j.jsams.2013.07.006. PubMed PMID: 23932441. 
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
37. Irwin C, Desbrow B, Ellis A, O'Keeffe B, Grant G, Leveritt M. Caffeine withdrawal and 
high-intensity endurance cycling performance. Journal of sports sciences. 2011;29(5):509-15. 
Epub 2011/02/01. doi: 10.1080/02640414.2010.541480. PubMed PMID: 21279864. 
38. Goncalves LS, Painelli VS, Yamaguchi G, Oliveira LF, Saunders B, da Silva RP, et al. 
Dispelling the myth that habitual caffeine consumption influences the performance response to 
acute caffeine supplementation. Journal of applied physiology (Bethesda, Md : 1985). 
2017;123(1):213-20. Epub 2017/05/13. doi: 10.1152/japplphysiol.00260.2017. PubMed PMID: 
28495846. 
39. Skinner TL, Jenkins DG, Taaffe DR, Leveritt MD, Coombes JS. Coinciding exercise 
with peak serum caffeine does not improve cycling performance. Journal of science and 
medicine in sport. 2013;16(1):54-9. Epub 2012/06/05. doi: 10.1016/j.jsams.2012.04.004. 
PubMed PMID: 22658588. 
40. Beedie CJ, Stuart EM, Coleman DA, Foad AJ. Placebo effects of caffeine on cycling 
performance. Medicine and science in sports and exercise. 2006;38(12):2159-64. PubMed 
PMID: ISI:000242669100017. 
 
  
Copyright © 2019 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Figures 
Figure 1 Percentage change in performance time with caffeine relative to placebo in men and 
women. Positive values indicate improved performance. Values are mean±SD. 
Figure 2 Plasma caffeine concentrations pre- and post-exercise in men and women. Values are 
mean±SD. * denotes a significant difference between sexes (p <0.001); 
†
 denotes a significant 
difference pre- to post-exercise (p = 0.008).  
Figure 3 Relationship between pre-trial (A) and post-trial (B) plasma caffeine concentration and 
percent difference in performance between caffeine and placebo trials. Positive values indicate 
improved performance with caffeine. Values are mean±SD.   
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 3b 
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Table 1 Characteristics of participants undertaking caffeine and placebo cycling time trials 
 
Women  
(n=11) 
Men  
(n=16) p-value 
Age (years) 29.7 ± 5.3 32.6 ± 8.3 0.318 
Body mass (kg) 59.5 ± 9.7 78.5 ± 6.0 0.001* 
Body mass index (kg·m
-2
) 21.9 ± 2.7 24.0 ± 1.3 0.014* 
Usual caffeine intake (mg·day
-1
) 
122.1 ± 74.6 
253.1 ± 
227.8 0.168 
Peak aerobic capacity (mL·kg·
-
1
min
-1
) 51.9 ± 7.2 60.4 ± 4.1  0.001* 
Peak power output (W) 234.9 ± 26.4 375.0 ± 
33.4 
 0.001* 
         Data presented as mean±SD. * denotes a significant difference between sexes. 
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Table 2 Performance time, heart rate and rating of perceived exertion outcomes 
    Women        Men      
p-
value 
  Caffeine  Placebo  
p-
value  Caffeine  Placebo  p-value  
            Performance 
time (sec) 
 
3757 
(3720-
4072) 
3863 
(3771-
4320) 
0.014 3734±287 3903±341 <0.001 0.321 
Rating of 
perceived 
exertion score 
a 
 
15.7±1.5 15.5±1.7 0.309 16.1±0.87 16.1±1.04 0.695 0.956 
Heart rate  
(beats per min) 
168.2±8.5 165.5±10.2 0.042 169.8±12.6 163.4±12.7 <0.001 0.290 
                        
Values are mean±SD or median and interquartile range where appropriate. 
a
 n=24 
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